The Vulvar Immunohistochemical Panel (VIP) Project: Molecular Profiles of Vulvar Squamous Cell Carcinoma.
biostatistics
gynecological cancers
immunohistochemistry
molecular targets
squamous cell carcinoma
vulvar cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
19 Dec 2021
19 Dec 2021
Historique:
received:
02
10
2021
revised:
25
11
2021
accepted:
13
12
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
25
12
2021
Statut:
epublish
Résumé
The study's aim was to investigate the immunohistochemical (IHC) expression of biological markers as potential prognostic/therapeutic factors in vulvar squamous cell carcinoma (VSCC). A series of 101 patients surgically treated at our center from 2016 to 2020 were retrospectively enrolled: 53 node-negative (Group A) and 48 node-positive (Group B). A total of 146 samples, 101 from primary tumor (T) and 45 from nodal metastases (N), were investigated. The IHC panel included: p16, p53, MLH1, MSH2, MSH6, PMS2, PD-L1, CD3, HER2/neu, ER, PR, EGFR, VEGF, and CD31. The reactions were evaluated on qualitative and semi-quantitative scales. Generalized Linear Model (GLM) and cluster analysis were performed in R statistical environment. A distance plot compared the IHC panel of T with the correspondent N. In Group A: p16-positive expression (surrogate of HPV-dependent pathway) was significantly higher (20.8% vs. 6.2%, Our results support a potential role of immune checkpoint inhibitors and anti-VEGF and anti-EGFR drugs especially in patients with worse prognosis (metastatic, HPV-independent). A panel including EGFR, VEGF, PDL1, p16, and p53 might be performed routinely in primary tumor and repeated in case of lymph node metastases to identify changes in marker expression.
Identifiants
pubmed: 34944993
pii: cancers13246373
doi: 10.3390/cancers13246373
pmc: PMC8699435
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Gynecol Oncol. 2018 Sep;150(3):552-561
pubmed: 29980281
Int J Gynecol Cancer. 2020 Jul;30(7):932-938
pubmed: 32474446
Eur J Surg Oncol. 2017 Sep;43(9):1776-1783
pubmed: 28751058
J Natl Cancer Inst. 2015 Jan 24;107(3):
pubmed: 25618900
Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3303-3314
pubmed: 33619601
Int J Gynecol Cancer. 2017 Jul;27(6):1237-1246
pubmed: 28448304
Gynecol Oncol. 2001 Jun;81(3):348-54
pubmed: 11371121
Diagnostics (Basel). 2021 Apr 16;11(4):
pubmed: 33923427
J Cancer Res Clin Oncol. 2020 Jul;146(7):1647-1658
pubmed: 32335720
Int J Mol Sci. 2020 Dec 27;22(1):
pubmed: 33375467
Int J Gynecol Cancer. 2020 Jul;30(7):927-931
pubmed: 32371425
JCO Precis Oncol. 2020 Jun 16;4:
pubmed: 32923875
Oncotarget. 2017 Sep 15;8(52):89903-89912
pubmed: 29163797
Ultrasound Obstet Gynecol. 2021 Nov;58(5):766-772
pubmed: 33587289
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Eur J Cancer. 2013 Nov;49(16):3450-61
pubmed: 23886586
Tumori. 2021 Jul 21;:3008916211027627
pubmed: 34289750
Ultrasound Obstet Gynecol. 2021 Jun;57(6):861-879
pubmed: 34077608
Gynecol Oncol. 2021 Oct;163(1):117-124
pubmed: 34301412
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
Gynecol Oncol. 1997 Jun;65(3):425-9
pubmed: 9190969
Histopathology. 2013 Jan;62(1):161-75
pubmed: 23190170
J Nucl Med. 2018 Jul 20;:
pubmed: 30030346
Oncotarget. 2017 Oct 6;8(54):92890-92903
pubmed: 29190964
Gynecol Oncol. 2008 Nov;111(2):289-97
pubmed: 18768215
J Cancer Res Clin Oncol. 2019 Sep;145(9):2211-2225
pubmed: 31297606
Sci Rep. 2021 Mar 11;11(1):5661
pubmed: 33707570
Gynecol Oncol. 2015 Jan;136(1):143-57
pubmed: 25448458
N Engl J Med. 2021 Nov 11;385(20):1856-1867
pubmed: 34534429
Gynecol Oncol. 2014 Mar;132(3):780-9
pubmed: 24296343
Gynecol Oncol. 2012 Oct;127(1):141-6
pubmed: 22750258
Int J Gynecol Cancer. 2019 Jan 23;:
pubmed: 30674571
Clin Nucl Med. 2021 Feb 1;46(2):125-132
pubmed: 33234921
Clin Transl Oncol. 2021 Aug;23(8):1611-1619
pubmed: 33650029
Virchows Arch. 2018 Oct;473(4):513-516
pubmed: 29736798
N Engl J Med. 2014 Feb 20;370(8):734-43
pubmed: 24552320
Gynecol Oncol. 2020 Aug;158(2):498-506
pubmed: 32522421
PLoS One. 2018 Sep 26;13(9):e0204162
pubmed: 30256833
Ultrasound Obstet Gynecol. 2020 Mar;55(3):401-410
pubmed: 31237047
Clin Cancer Res. 2017 Aug 1;23(15):4501-4510
pubmed: 28377483
Curr Opin Oncol. 2021 Sep 1;33(5):485-492
pubmed: 34319290
Gynecol Oncol. 2007 Jan;104(1):109-13
pubmed: 16963112
Microsurgery. 2017 Sep;37(6):516-524
pubmed: 27273808
Gynecol Oncol. 2019 Jan;152(1):208-217
pubmed: 30415992
Ultrasound Obstet Gynecol. 2019 Oct;54(4):545-551
pubmed: 31152573
J Nucl Med. 2017 Dec;58(12):1913-1918
pubmed: 28546331
Histopathology. 2019 Jan;74(2):256-268
pubmed: 30067880
PLoS One. 2017 Nov 28;12(11):e0188274
pubmed: 29182671
Gynecol Oncol. 2017 Aug;146(2):314-318
pubmed: 28527674
Clin Cancer Res. 2017 Nov 15;23(22):6781-6789
pubmed: 28899974
Microsurgery. 2017 Sep;37(6):564-573
pubmed: 27987230
Infect Agent Cancer. 2020 Apr 1;15:20
pubmed: 32266002
J Clin Oncol. 2012 Dec 10;30(35):4297-301
pubmed: 23150704
Ann Oncol. 2009 Sep;20(9):1511-1516
pubmed: 19487487
JAMA Oncol. 2016 Apr;2(4):518-22
pubmed: 26913631
Oncology. 2009;77(5):281-4
pubmed: 19923866
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1261-1274
pubmed: 31897584
Gynecol Oncol. 2020 Sep;158(3):519-520
pubmed: 32912480
Int J Gynecol Cancer. 2020 Jan;30(1):107-114
pubmed: 31801791
J Gynecol Oncol. 2016 Nov;27(6):e60
pubmed: 27550406